Clinically, the natural product HDAC inhibitor romidepsin (IstodaxTM) and SAHA (vorinostat, ZolinzaTM) are used for the treatment of cutaneous T-cell lymphoma [34,35]. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.